Adenovirus Vector-based Vaccine for Infectious Diseases

Overview

Journal Drug Metab Pharmacokinet

Publisher Elsevier

Specialties Endocrinology
Pharmacology

Date 2022 Jan 2

PMID 34974335

Citations 49

Authors

Fuminori Sakurai

Masashi Tachibana

Hiroyuki Mizuguchi

Affiliations

Soon will be listed here.

Abstract

Replication-incompetent adenovirus (Ad) vectors have been widely used as gene delivery vehicles in both gene therapy studies and basic studies for gene function analysis due to their highly advantageous properties, which include high transduction efficiencies, relatively large capacities for transgenes, and high titer production. In addition, Ad vectors induce moderate levels of innate immunity and have relatively high thermostability, making them very attractive as potential vaccine vectors. Accordingly, it is anticipated that Ad vectors will be used in vaccines for the prevention of infectious diseases, including Ebola virus disease and acquired immune deficiency syndrome (AIDS). Much attention is currently focused on the potential use of an Ad vector vaccine for coronavirus disease 2019 (COVID-19). In this review, we describe the basic properties of an Ad vector, Ad vector-induced innate immunity and immune responses to Ad vector-produced transgene products. Development of novel Ad vectors which can overcome the drawbacks of conventional Ad vector vaccines and clinical application of Ad vector vaccines to several infectious diseases are also discussed.

Citing Articles

Progress in African Swine Fever Vector Vaccine Development.

Yang Y, Yuan H, Zhang Y, Luan J, Wang H Int J Mol Sci. 2025; 26(3).

PMID: 39940691 PMC: 11816837. DOI: 10.3390/ijms26030921.

Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trial.

Tica J, Rezelj V, Baron B, van Paassen V, Zaidman J, Fairlie L Hum Vaccin Immunother. 2025; 21(1):2450120.

PMID: 39868766 PMC: 11776467. DOI: 10.1080/21645515.2025.2450120.

Adenoviral Vectors for Gene Therapy of Hereditary Diseases.

Muravyeva A, Smirnikhina S Biology (Basel). 2025; 13(12.

PMID: 39765719 PMC: 11673936. DOI: 10.3390/biology13121052.

Regulation of protein thermal stability and its potential application in the development of thermo-attenuated vaccines.

Wang M, Wu C, Liu N, Jiang X, Dong H, Zhao S Eng Microbiol. 2024; 4(3):100162.

PMID: 39629114 PMC: 11610959. DOI: 10.1016/j.engmic.2024.100162.

Enhanced Humoral and Cellular Immune Responses Elicited by Adenoviral Delivery of SARS-CoV-2 Receptor-Binding Motif Fused to Human Fc.

Lee Y, Easwaran M, Jung Y, Qian Y, Shin H Vaccines (Basel). 2024; 12(11).

PMID: 39591150 PMC: 11598816. DOI: 10.3390/vaccines12111247.

References

Johnstone R, Loveland B, McKenzie I . Identification and quantification of complement regulator CD46 on normal human tissues. Immunology. 1993; 79(3):341-7. PMC: 1421998. View

Roberts D, Nanda A, Havenga M, Abbink P, Lynch D, Ewald B . Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature. 2006; 441(7090):239-43. DOI: 10.1038/nature04721. View

Hage E, Liebert U, Bergs S, Ganzenmueller T, Heim A . Human mastadenovirus type 70: a novel, multiple recombinant species D mastadenovirus isolated from diarrhoeal faeces of a haematopoietic stem cell transplantation recipient. J Gen Virol. 2015; 96(9):2734-2742. DOI: 10.1099/vir.0.000196. View

Sorensen A, Rolland M, Hartmann J, Harboe Z, Roed C, Jensen T . A case of thrombocytopenia and multiple thromboses after vaccination with ChAdOx1 nCoV-19 against SARS-CoV-2. Blood Adv. 2021; 5(12):2569-2574. PMC: 8219289. DOI: 10.1182/bloodadvances.2021004904. View

ORiordan C, Lachapelle A, Delgado C, Parkes V, Wadsworth S, Smith A . PEGylation of adenovirus with retention of infectivity and protection from neutralizing antibody in vitro and in vivo. Hum Gene Ther. 1999; 10(8):1349-58. DOI: 10.1089/10430349950018021. View

Anghelina D, Lam E, Falck-Pedersen E . Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity. J Virol. 2016; 90(13):5915-27. PMC: 4907218. DOI: 10.1128/JVI.00500-16. View

Provine N, Amini A, Garner L, Spencer A, Dold C, Hutchings C . MAIT cell activation augments adenovirus vector vaccine immunogenicity. Science. 2021; 371(6528):521-526. PMC: 7610941. DOI: 10.1126/science.aax8819. View

Cerullo V, Seiler M, Mane V, Brunetti-Pierri N, Clarke C, Bertin T . Toll-like receptor 9 triggers an innate immune response to helper-dependent adenoviral vectors. Mol Ther. 2007; 15(2):378-85. DOI: 10.1038/sj.mt.6300031. View

Abbink P, Lemckert A, Ewald B, Lynch D, Denholtz M, Smits S . Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol. 2007; 81(9):4654-63. PMC: 1900173. DOI: 10.1128/JVI.02696-06. View

10.

Walters R, Grunst T, Bergelson J, Finberg R, Welsh M, Zabner J . Basolateral localization of fiber receptors limits adenovirus infection from the apical surface of airway epithelia. J Biol Chem. 1999; 274(15):10219-26. DOI: 10.1074/jbc.274.15.10219. View

11.

Hwang J, Lee S, Lee S, Lee M, Koyanagi A, Jacob L . Comparison of vaccine-induced thrombotic events between ChAdOx1 nCoV-19 and Ad26.COV.2.S vaccines. J Autoimmun. 2021; 122:102681. PMC: 8204660. DOI: 10.1016/j.jaut.2021.102681. View

12.

Hayton E, Rose A, Ibrahimsa U, Del Sorbo M, Capone S, Crook A . Safety and tolerability of conserved region vaccines vectored by plasmid DNA, simian adenovirus and modified vaccinia virus ankara administered to human immunodeficiency virus type 1-uninfected adults in a randomized, single-blind phase I trial. PLoS One. 2014; 9(7):e101591. PMC: 4090156. DOI: 10.1371/journal.pone.0101591. View

13.

Van Kampen K, Shi Z, Gao P, Zhang J, Foster K, Chen D . Safety and immunogenicity of adenovirus-vectored nasal and epicutaneous influenza vaccines in humans. Vaccine. 2004; 23(8):1029-36. DOI: 10.1016/j.vaccine.2004.07.043. View

14.

Luo S, Zhang P, Ma X, Wang Q, Lu J, Liu B . A rapid strategy for constructing novel simian adenovirus vectors with high viral titer and expressing highly antigenic proteins applicable for vaccine development. Virus Res. 2019; 268:1-10. DOI: 10.1016/j.virusres.2019.05.008. View

15.

Wickham T, Mathias P, Cheresh D, Nemerow G . Integrins alpha v beta 3 and alpha v beta 5 promote adenovirus internalization but not virus attachment. Cell. 1993; 73(2):309-19. DOI: 10.1016/0092-8674(93)90231-e. View

16.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

17.

Segerman A, Atkinson J, Marttila M, Dennerquist V, Wadell G, Arnberg N . Adenovirus type 11 uses CD46 as a cellular receptor. J Virol. 2003; 77(17):9183-91. PMC: 187375. DOI: 10.1128/jvi.77.17.9183-9191.2003. View

18.

Chan J, Kok K, Zhu Z, Chu H, To K, Yuan S . Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect. 2020; 9(1):221-236. PMC: 7067204. DOI: 10.1080/22221751.2020.1719902. View

19.

Atasheva S, Yao J, Shayakhmetov D . Innate immunity to adenovirus: lessons from mice. FEBS Lett. 2019; 593(24):3461-3483. PMC: 6928416. DOI: 10.1002/1873-3468.13696. View

20.

Baden L, Stieh D, Sarnecki M, Walsh S, Tomaras G, Kublin J . Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study. Lancet HIV. 2020; 7(10):e688-e698. PMC: 7529856. DOI: 10.1016/S2352-3018(20)30229-0. View